Valsartan produced a substantial reduction in rat myocardial appearance of TIMP-1 and MMP-1 mRNA ( 0.01) and a substantial upsurge in the proportion of MMP-1/TIMP-1 ( 0.01). of regulation of TIMP-1 and MMP-1 expression in the myocardial rat. 1. Launch Myocardial fibrosis is normally common in a number of cardiovascular diseases, which is also a significant pathologic element in a number of cardiovascular occasions (including ramifications of center failing, arrhythmia, and unexpected cardiac loss of life) [1]. Unusual reconstruction of broken center tissue, seen as a myocardial fibrosis, is normally a primary pathological change observed in various kinds of chronic coronary disease [2]. As a result, developing a highly effective medication treatment has turned into a concentrate of medical analysis into myocardial fibrosis. Presently, such analysis in western medication has centered on the renin-angiotensin-aldosterone program (RAAS), specifically on angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARB), and aldosterone antagonists, that are known to have got a definite healing effect [3]. Nevertheless, traditional Chinese medication (TCM) gets the advantage of concentrating on many the different parts of something and providing even more integrated legislation than modern medication, which will target an individual pathological hyperlink [4]. In concentrating on myocardial fibrosis, we make an effort to treat coronary disease early by TCM, in order to enhance the cardiac microenvironment, promote constant recovery, and even inhibit or reverse the myocardial (+)-Corynoline fibrosis. QiShenYiQi is usually a TCM composed ofRadix AstragaliRadix Salviae miltiorrhizaeRadix NotoginsengLignum Dalbergia Odorifera[5, 6]. QiShenYiQi pill (QSYQ) is approved by China State Food and Drug Administration in 2003 for treatment (+)-Corynoline of coronary heart disease, angina pectoris [7]. QSYQ enables a stable dosage form, of which the main effective ingredients are astragaloside, tanshinol, protocatechualdehyde, and ginsenosides Rg1 and Rb1 TRUNDD [8, 9]. Astragaloside is the main effective component ofRadix AstragaliRadix Salviae miltiorrhizaeRadix Notoginseng 0.05. 3. Results 3.1. Effect of QSYQ on Systolic Blood Pressure Compared with the sham-operated group, systolic blood pressure (SBP) was increased significantly in model group ( 0.01) and showed a tendency to increase over time. SBP significantly reduced in the valsartan group compared with the model group ( 0.01), while there was no statistical difference in the QSYQ group ( 0.05). And SBP was lower in the valsartan group than in the QYSQ group ( 0.01) (Physique 1). Open in a separate window Physique 1 Effect of QSYQ on systolic blood pressure. Groups: control (= 8), model (= 8), valsartan (= 8), and QSYQ (= 8). Data are expressed as mean SD. ** 0.01. 3.2. Effect of QSYQ on HMI and LVMI Compared with the sham-operated group, the HMI and LVMI were increased significantly in model group ( 0.01), and they increased further over time. With regard to the two treatment groups, the HMI and LVMI were significantly reduced in both the valsartan and the QSYQ group ( 0.01), and this reduction was greater over time. But the HMI and LVMI were just lower in the QSYQ group than in the valsartan group at 8 weeks ( 0.05) (Figure 2). Open in a separate windows Physique 2 Effect of QSYQ on HMI and LVMI. (a) HMI of each group. (b) LVMI of each group. Groups: control (= 8), model (= 8), valsartan (= 8), and QSYQ (= 8). Data are expressed as mean SD. * 0.05, ** 0.01. 3.3. Effect of QSYQ on HYP Content Compared with the sham-operated control group, the content of myocardial HYP was increased significantly in the model group at 4 weeks ( 0.01), and it increased further over time, being higher again at 8 weeks ( 0.01). With regard to the two treatment groups, the content of myocardial HYP was significantly reduced ( 0.01) in both (+)-Corynoline the valsartan and the QSYQ group after 4 weeks. Even though HYP content experienced risen by 8 weeks, it was lower in the QSYQ group than in the valsartan group ( 0.01) (Physique 3). Open in a separate window Physique 3 Effect of QSYQ on the content of HYP in rats with partial abdominal aortic coarctation. Groups: sham-operated control (= 8), model (= 8), valsartan (= 8), and QSYQ (= 8). Data are expressed as mean SD. ** 0.01. 3.4. Effect of QSYQ around the Synthesis and Degradation of Myocardial Collagen Compared with the sham-operated control group, the concentration of serum PICP and PIIINP and the ratio of PICP/PIIINP increased significantly ( 0.01) in the model group and showed a tendency to increase over time. Valsartan significantly decreased the concentration of serum PICP and PIIIN ( 0.01 and 0.05, resp.) and significantly decreased the ratio of PICP/PIIINP at 8 weeks ( 0.05). A similar result was seen with the QSYQ group, except that its effect was significantly greater (+)-Corynoline than that of valsartan at 8 weeks ( 0.01, 0.05) (Figure 4). Open in a.